Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Briviact
Synonyms :
brivaracetam
Class :
SV2A Ligands
Brand Name :
Briviact
Synonyms :
brivaracetam
Class :
SV2A Ligands
Dosage Forms & StrengthsÂ
TabletÂ
10mgÂ
25mgÂ
50mgÂ
75mgÂ
100mgÂ
Oral solutionÂ
10mg/mLÂ
Injection solutionÂ
50mg/5mL single-dose vialÂ
50 mg orally/IV 2 times a day; dose can be adjusted b/w 25-100 mg orally/IV
When oral delivery is temporarily unfeasible, patients may use injections;
however, clinical study experience with injection is only available for 4 consecutive days of treatment
Note:
Used to treat partial-onset seizures
Dosage Forms & StrengthsÂ
TabletÂ
10mgÂ
25mgÂ
50mgÂ
75mgÂ
100mgÂ
Oral solutionÂ
10mg/mLÂ
Injection solutionÂ
50mg/5mL single-dose vialÂ
Age: 1 month-16 years
Wt <11 kg: 0.75-1.5 mg/kg orally every 12 hours; may be increased to 0.75-3 mg/kg
Wt 11-<20 kg: 0.5-1.25 mg/kg orally every 12 hours; may be increased to 0.5 to 2.5 mg/kg
Wt 20-<50 kg: 0.5 to 1 mg/kg orally every 12 hours; may be increased to 0.5 to 2 mg/kg
Wt ≥50 kg: 25-50 mg orally every 12 hours; may be increased to 25 to 100 mg
Age: ≥16 years
50 mg orally every 12 hours; may be increased to 25 mg-100 mg
Note:
Used to treat partial-onset seizures
Refer to adult dosingÂ
CYP2C19 Inducers: they may diminish the serum concentration of brivaracetam
CYP2C19 Inducers: they may diminish the serum concentration of brivaracetam
CYP2C19 Inducers: they may diminish the serum concentration of brivaracetam
CYP2C19 Inducers: they may diminish the serum concentration of brivaracetam
CYP2C19 Inducers: they may diminish the serum concentration of brivaracetam
It may enhance sedation when combined with oxycodone
CYP2C19 enhancers (moderate) may reduce the therapeutic efficacy of brivaracetam 
may increase the adverse effect of Immunosuppressants
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
brivaracetam and codeine lead to increased sedative effects
may enhance the concentration of serum when combined with brivaracetam
may enhance the concentration of serum when combined with brivaracetam
it may diminish the metabolism when combined with diosmin
Combining brivaracetam with pranlukast may cause a reduction in the brivaracetam’s metabolism
The potential for increased CNS depression risk or seriousness occurs when brivaracetam is used together with pipecuronium
brivaracetam has the potential to reduce the rate of excretion of idebenone, leading to an elevation in levels of serum
When captodiame is used together with brivaracetam, There is a risk or seriousness of CNS depression is enhanced
When brivaracetam is used together with medazepam, the risk or seriousness of CNS depression is enhanced
The potential for CNS depression may enhanced when brivaracetam is used together with fencamfamin
When brivaracetam is used together with niaprazine, the risk or seriousness of CNS depression is enhanced
When brivaracetam is used together with levosulpiride, the risk or seriousness of CNS depression is enhanced
When brivaracetam is used together with fluconazole, this leads to reduction in the brivaracetam metabolism
tinidazole has the potential to reduce the rate of excretion of brivaracetam, potentially leading to an elevation in level of serum
When chlordiazepoxide is used together with brivaracetam, this leads to enhanced risk or seriousness of CNS depression
When brivaracetam is used together with capsaicin, this leads to enhanced risk or seriousness of methemoglobinemia
When brivaracetam is used together with norelgestromin, this leads to a rise in norelgestromin’s metabolism
When brivaracetam is used together with melitracen, this leads to enhanced risk or seriousness of CNS depression
When emylcamate is used together with brivaracetam, this leads to enhanced risk or seriousness of CNS depression
When brivaracetam is used together with etizolam, this leads to enhanced risk or seriousness of CNS depression
When acepromazine is used together with brivaracetam, this leads to enhanced risk or seriousness of CNS depression
brivaracetam leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
cefpirome leads to a reduction in the rate of excretion of brivaracetam which leads to increased level of serum
brivaracetam leads to a reduction in the rate of excretion of chromous sulfate, which leads to an increased level of serum
brivaracetam leads to a reduction in the rate of excretion of pentaerythritol tetranitrate, which leads to an increased level of serum
brivaracetam leads to a reduction in the rate of excretion of potassium acetate, which leads to an increased level of serum
brivaracetam leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
brivaracetam: it may decrease the excretion rate of iothalamic acid
brivaracetam: it may increase the excretion rate of oxtriphylline
brivaracetam: it may increase the metabolism of CNS depressants
brivaracetam: it may increase the metabolism of CNS depressants
brivaracetam: it may increase the metabolism of CNS depressants
brivaracetam: it may increase the metabolism of CNS depressants
brivaracetam: it may increase the metabolism of CNS depressants
brivaracetam: it may increase the risk of CNS depression with pridinol
brivaracetam: it may increase the central nervous system depressant activities of tolperisone
brivaracetam: it may increase the metabolism of cerivastatin
brivaracetam may decrease the excretion rate of almasilate, leading to higher serum levels
Decreased therapeutic activity of brivaracetam.
it decreases the efficacy of antiseizure agents
may increase the toxic effect of anti-Parkinson agents
the rate of excretion of potassium nitrate may be reduced
brivaracetam might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
Actions and SpectrumÂ
The exact mechanism of action of brivaracetam is not fully understood but it is believed to work by binding to a specific type of receptor in the brain called the synaptic vesicle protein 2A (SV2A) receptor. This binding is known to increase the release of neurotransmitters such as GABA which helps to reduce seizures.Â
The spectrum of activity of brivaracetam includes the treatment of seizures and other neurological conditions such as anxiety and depression. Â
Frequency DefinedÂ
>10%Â
Dizziness (12%)Â
Somnolence and sedation (16%)Â
1-10%Â
Nausea and vomiting (5%)Â
Constipation (2%)Â
Fatigue (9%)Â
Irritability (3%)Â
Black Box WarningÂ
The FDA has issued a black box warning for brivaracetam that patients with signs of suicidal thoughts or behaviour need to be very carefully monitored and informed about potential risk of suicide to the health care providers.Â
Contraindication/Caution:Â
ContraindicationÂ
HypersensitivityÂ
Caution:Â
Use with extreme care in patients with moderate to severe renal impairment. Â
Do not prescribe to patients with a history of depression or suicidal tendencies. Â
It is advisable to refrain from alcohol and other central nervous system depressants to minimize the chances of any sedation and drowsiness.Â
Pregnancy/LactationÂ
Pregnancy warnings:Â
AU TGA pregnancy category: B3 US FDA pregnancy category: Not assignedÂ
Lactation:Â
Excreted into human milk is knownÂ
Pregnancy Categories:Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in the first or second trimester.Â
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.  Â
Category C: There was evidence of risk of adverse effects in animal reproduction studies, and there was no adequate evidence in human studies that must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
PharmacologyÂ
It is prescribed for the partial onset seizures management in the epilepsy. It is attached to SV2A through an L-type of milligram ion channel at the presynaptic membrane. The process of exocytosis is controlled by the action of this protein and responsible for synaptic vesicles discharge of neurotransmitters in the space between a presynaptic neuron and a postsynaptic neuron. The ligand interaction with SV2A explains the effective seizure attenuation that is brought by agents like brivaracetam.Â
PharmacodynamicsÂ
brivaracetam’s role in the anti-epileptogenic system may be increased by its capacity to block Na+ channels. It is thought that the anti-epileptogenic actions come from its connection with SV2A receptors which regulate synaptic GABA release.Â
Pharmacokinetics:Â
AbsorptionÂ
The drug has 100% oral bioavailability. It undergoes fast and complete absorption with a peak plasma time of one hour.Â
DistributionÂ
The volume of distribution is 0.5 L/kg. The protein binding is less than 20%.Â
MetabolismÂ
The main metabolic process is the breakdown of carboxylic acid moieties which forms carboxylic acid metabolites and the oxidation of propionate by enzymes such as CYP2C8, CYP2C19 and CYP2B6 which forms another metabolite.Â
Elimination and excretionÂ
Over 95% of the drug is eliminated from the body through urine while 10% remains unchanged. Only 1% of total water is eliminated through the feces. The drug has a half-life in the range of 7 to 8 hours. Â
AdministrationÂ
It is taken orally in the form of tabletsÂ
Patient information leafletÂ
Generic Name: brivaracetamÂ
Why do we use brivaracetam?Â
It is a newly developed antiepileptic drug that targets in certain areas on the nerve cells. This chemical binding basically replaces the irregular activity of the nerve cells within the brain and thus impedes the spread of electrical messages that are responsible for seizures.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
